Table 1.
Adverse event | Before third vaccine dose, N = 56 (100%) | After third vaccine dose, N = 56 (100%) | P value | Low-Ra, N = 26 (100%) | High-Rb, N = 30 (100%) | P value | ||
---|---|---|---|---|---|---|---|---|
N (%) | CTCAE Grading | N (%) | CTCAE Grading | N (%) | N (%) | |||
Thyroiditis | 8 (14.3%) | 1–2 | 3 (5.3%) | 2–3 | 0.13 | 2 (7.7%) | 9 (30%) | 0.036† |
Skin rash | 4 (7.1%) | 1–2 | 1 (1.8%) | 2 | 0.17 | 2 (7.7%) | 3 (10%) | 0.76 |
Pancreatitis | 3 (5.3%) | 2 | 1 (1.8%) | 2 | 0.31 | 3 (11.5%) | 1 (3.3%) | 0.23 |
Colitis | 3 (5.3%) | 2 | 1 (1.8%) | 2 | 0.31 | 1 (3.8%) | 3 (10%) | 0.37 |
Hepatitis | 2 (3.5%) | 2 | 1 (1.8%) | 2 | 0.56 | 1 (3.8%) | 2 (6.6%) | 0.63 |
Pneumonitis | 2 (3.5%) | 2 | – | – | 0.15 | – | 2 (6.6%) | 0.17 |
Arthritis | 2 (3.5%) | 1–2 | 2 (3.5%) | 2 | 1.00 | 2 (7.7%) | 2 (6.6%) | 0.88 |
Myositis | – | – | 1 (1.8%) | 2 | 0.31 | – | 1 (3.3%) | 0.34 |
Vasculitis | – | – | 1 (1.8%) | 3 | 0.31 | 1 (3.8%) | – | 0.27 |
Uveitis | – | – | 1 (1.8%) | 2 | 0.31 | – | 1 (3.3%) | 0.34 |
CTCAE common terminology criteria for adverse events, version 5.0
aLow-R indicates the subgroup of patients with an anti-RBD-S1 IgG titer < 486 BAU/mL after the third dose of vaccine
bHigh-R indicates the subgroup of patients with an anti-RBD-S1 IgG titer ≥ 486 BAU/mL after the third dose of vaccine,
†Statistical significance not maintained after Holm-Bonferroni p value correction for multiple comparisons